As of 2025-07-06, the Fair Value of Monopar Therapeutics Inc (MNPR) is -13.54 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 36.25 USD, the upside of Monopar Therapeutics Inc is -137.36%.
With the market price of 36.25 USD and our fair value calculation, Monopar Therapeutics Inc (MNPR) is not a good investment. Investing in MNPR stocks now will result in a potential loss of 137.36%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -6.30 | -9.10 | -10.52 | -8.40 | -16.00 | -10.06 |
| YoY growth | -49.29% | -44.44% | -15.60% | 20.15% | -90.48% | -35.93% |
| Market Cap (mil) | 221.85 |
| P/E | |
| Forward P/E |
| EPS | -2.71 |
| Avg earnings growth rate | -35.93% |
| TTM earnings | -16.57 |